Welcome to Tridek-One

Restoring the immune balance

Tridek-One develops first-in-class CD31 checkpoint agonists for the treatment of auto-immune diseases

About us

Tridek-One is a spin-off from INSERM that develops first-in-class therapeutic agonistic antibodies targeting immune checkpoint inhibitory receptors for the treatment of autoimmune and inflammatory diseases.

The company primarily focuses on the research and development of first-in-class anti-CD31 agonistic modalities designed to restore the immune balance. Anti-CD31 agonistic antibodies have the potential to provide targeted immunomodulatory activity with a favorable safety profile in diseases with high unmet clinical needs.

Fully leveraging its understanding of inhibitory checkpoint receptor modulation and agonistic antibodies engineering, a second discovery program was initiated for a novel therapeutic target.

Tridek-One is financed by leading European investors and led by an experienced management team.

Our Team


SVP Biologics Engineering

Scientific team

Group Leader
Senior Laboratory Technician

Antibody-mediated CD31 agonism inhibits
activatory signal induced by ITAM receptors

Scientific rationale

Mode of action of ITIM receptors

  • CD31 belongs to a family of receptors harboring immunoreceptor tyrosine-based inhibitory motifs (ITIMs).
  • ITIMs recruit and activate the tyrosine phosphatases SHP-1 and SHP-2, which can inhibit signaling pathways downstream of various ITAM immunoreceptors, leading to suppression of leukocyte activation.

Targeting CD31 and therapeutic opportunities

CD31 also known as PECAM-1 is a unique ITIM immunoreceptor due to its expression on the surface of cells from the innate and the adaptive immune system. CD31 agonists could potentially modulate:

  • Neutrophil activation and recruitment during inflammation helping to promote the resolution of inflammation and prevent tissue damage;
  • T cell activation by inhibiting signaling pathways downstream of TCRs leading to decreased T cell activation, proliferation, and cytokine production;
  • B cell signaling by inhibiting the activation of the BCR leading to decreased B cell activation, proliferation, and antibody production.


Possible indications allow for niche to blockbuster drugs potential

Antibody-mediated CD31 agonism inhibits activatory signal induced by ITAM receptors

Scientific rational

Antibody-mediated CD31 agonism inhibits
activatory signal induced by ITAM receptors

Board Of Directors


Chairman of the Board
AdBio Partners
Bpifrance Investissements
Advent Life Sciences
Independent member


Bioqube Ventures
Pureos Bioventures

Scientific founders


Tridek-One announced on September 15 2022 that it has closed a 16 million ($16.1M) new financing round led by Swiss Pureos Bioventures with the participation of new investors Bpifrance and Bioqube Ventures (Belgium), as well as historical investors AdBio partners and Advent Life Sciences. The funds are primarily be used to identify development candidates against auto-immune diseases, to conduct IND-enabling studies and to further build the organization.  

The company previously raised €3M ($3.02M) in a first round in 2019 involving AdBio partners (FR) and Advent Life Sciences (UK). 


Daniela Chmiest-Silin, PhD

Daniela obtained a PhD in Molecular and Cellular Biology from the Paris-Saclay University (2015), followed by postdoctoral training in immunology at the University of Lausanne, where she explored novel group of biomarkers monitoring response to PD1 immune checkpoint pathway. She has a broad experience in development of cell-based assays and